Recent research projects focus on prices of drugs in the US and other countries, intellectual property regulation of pharmaceuticals, and FDA policy and regulation. Dr. Seoane conducted more than 40 research projects for a variety of sponsors including the Agency for Healthcare Research and Quality, the Food and Drug Administration, the Kaiser Family Foundation, the Robert Wood Johnson Foundation, Ohio Medicaid, Ohio Public Employees Retirement System, the Inter-American Development Bank, the World Bank, and the World Health Organization. In 2004, he served as the pharmacy expert in the Ohio Commission to Reform Medicaid. Columbus of the Ohio Department of Job and Family Services. He also conducted research for governments, organizations, and associations of a dozen countries. Dr. Seoane published more than 60 articles and 125 abstracts in reference journals including the New England Journal of Medicine, the American Journal of Cardiology, PLoS One, Health Policy, and Value in Health. He has given more than 200 national and international presentations in his areas of expertise.
Dr. Seoane is the past-Chair of the Drug Policy and Pharmaceutical Services Committee of the American Public Health Association,
Google Scholar: https://scholar.google.com/citations?user=coZhsJ8AAAAJ&hl=en
Research Gate: https://www.researchgate.net/profile/enrique_seoane-vazquez
Dr. Seoane's areas of research interest relate to pharmaceutical economics, regulation
Dr. Seoane has extensive experience in the area of health economics and outcomes
Recent Creative, Scholarly Work and Publications
Ahmed Alghamdi, Enrique Seoane, Rosa Rodriguez-Monguio. Analysis of Formulary Coverage and Cost of Biologic Disease-Modifying Anti-Rheumatic Drugs in Medicare Part D. Journal of Pharmaceutical Health Services Research. May 23, 2018;1-8.
Minette-Joëlle Zeukeng, Enrique Seoane, Pascal Bonnabry. Response to the Letter to the editor regarding Zeukeng et al article A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: An assessment of the international harmonization of drugs. European Journal of Clinical Pharmacology 2018;74)6):811–81.
Kevin Kron, Sara Myers, Lynn Volk, Aaron Nathan, Pamela Neri, Alejandra Salazar, Mary Amato, Adam Wright, Sam Karmiy, Sarah McCord, Enrique Seoane, Tewodros Eguale, Rosa Rodriguez-Monguio, David Bates, Gordon Schiff. Incorporating Medication Indications into the Prescribing Process. American Journal of Health-Systems Pharmacy 2018; 75:e305-14.
Minette-Joëlle Zeukeng, Enrique Seoane, Pascal Bonnabry. A Comparison of New Drug Approved by the FDA, the EMA
Christina S. Kwon, Enrique Seoane, Rosa Rodriguez-Monguio. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of Type 2 Diabetes. BMC Health Services Research 2018;18(1):78.
Bander Balkhi, Enrique Seoane, Rosa Rodriguez-Monguio. Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication. Saudi Pharmaceutical Journal 2017;25(8).
Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio, Saad Alqahtani, Gordon Schiff. Exploring the Potential for Using Drug Indications to Prevent Look-Alike and Sound-Alike Drug Errors. Expert Opinion on Drug Safety 2017;16(10):1103-1109.
Richard A. Hansen, Jingjing Qian, Richard L. Berg, James G. Linneman, Enrique Seoane, Sarah Dutcher, Saeid Raofi, C. David Page, Peggy L. Peissig. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2017;37(4):429-437.
Aseel Bin Sawad. Enrique Seoane, Rosa Rodriguez-Monguio, Fatema Turkistani. Cost-Effectiveness of Different Strategies for Treatment of Relapsing-Remitting Multiple Sclerosis. Journal of Comparative Effectiveness Research 2017;6(2):97-108.
Bander Balkhi, Enrique Seoane, Rosa Rodriguez-Monguio. Osteoporosis Drugs Generic Competition, Pricing Structure
Rosa Rodriguez-Monguio, Tai Spargo, Enrique Seoane. Ethical imperatives of timely access to Orphan Drugs: Is possible to reconcile economic incentives and patients’ health needs? Orphanet Journal of Rare Diseases 2017;12(1):1.
Richard A. Hansen, Jingjing Qian, Richard L. Berg, James G. Linneman, Enrique Seoane, Sarah Dutcher, Saeid Raofi, C. David Page, Peggy L. Peissig. Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug. Clinical Pharmacology & Therapeutic 2018;103(2):310-317.
Seoun Kwon, Enrique Seoane, Rosa Rodriguez-Monguio. FDA Safety Actions for Antidiabetic Drugs Marketed in the US, 1980-2015. International Journal of Risk and Safety in Medicine, 2016;28(4):197-211.
Leo F. Buckley, Enrique Seoane, Judy W.M. Cheng, Ahmed
Aseel Bin Sawad. Enrique Seoane, Rosa Rodriguez-Monguio, Fatema Turkistani. Evaluation of Using Expanded Disability Status Scale and Multiple Sclerosis Functional Composite as Clinical Endpoints in Multiple Sclerosis Clinical Trials: A Quantitative Meta-Analysis. Current Medical Research and Opinion 2016; 32(12):1969-1974.
Gordon Schiff, Enrique Seoane, Adam Wright. Incorporating indications into medication ordering: Time to enter the age of reason. New England Journal of Medicine 2016;375(4):306-309.
Bander Balkhi, Enrique Seoane, Rosa Rodriguez-Monguio. Medicaid Osteoporosis Drugs Utilization and Expenditures: The Effect of Generic Drugs Market Entry. Journal of Pharmaceutical Health Services Research 2016; 7(4): 217-224.
Aseel Bin Sawad, Enrique Seoane, Rosa Rodriguez-Monguio, Fatema Turkistan. Price Analysis of Multiple Sclerosis Disease-Modifying Therapies Marketed in the United States. Current Medical Research and Opinion 2016;32(11):1783-1788.
Mona Alsheikh, Enrique Seoane, Brian Rittenhouse, Erin Fox, John Fanikos. A Comparison of Drug Shortages in the Hospital Setting in the United States and Saudi Arabia: An Exploratory Analysis. Hospital Pharmacy 2016; 51(5):370-375.
Enrique Seoane, Rosa Rodriguez-Monguio, Richard Hansen. Interchangeability, Safety